Ferreira Marion, Secher Thomas, Heuze-Vourc'H Nathalie, Reckamp Karen L
INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, Boulevard Tonnellé, F-37032 Tours, France.
Faculté de Médecine, Université de Tours, F-37032 Tours, France.
Pharmaceutics. 2021 Jun 21;13(6):912. doi: 10.3390/pharmaceutics13060912.
Several types of antibodies (Abs) are currently used in non-small cell lung cancer (NSCLC). Anti-angiogenic and immune checkpoint inhibitor (ICI) Abs are the most frequent treatments used alone or with chemotherapy in metastatic NSCLC, for the front line and beyond. Considering the many therapeutic options for locally advanced and metastatic lung cancer and differences in use according to geographic area, we present here a comprehensive review of the marketed ICI and anti-angiogenic Abs approved in the European Union (EU) and the US to treat locally advanced and metastatic NSCLC patients. We briefly describe the different molecules and their development in thoracic oncology and compare pharmacokinetic data, processing decision algorithms and marketing authorizations by the EMA and US Food and Drug Administration (FDA).
目前，非小细胞肺癌（NSCLC）治疗中使用了几种类型的抗体（Abs）。抗血管生成和免疫检查点抑制剂（ICI）抗体是转移性NSCLC一线及后续治疗中最常用的单独或联合化疗的治疗方法。考虑到局部晚期和转移性肺癌的多种治疗选择以及不同地理区域的使用差异，我们在此对欧盟（EU）和美国批准用于治疗局部晚期和转移性NSCLC患者的上市ICI和抗血管生成抗体进行全面综述。我们简要描述了不同分子及其在胸科肿瘤学中的发展，并比较了EMA和美国食品药品监督管理局（FDA）的药代动力学数据、治疗决策算法和上市许可。
